Search

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The incidence of hepatitis C virus infection is commonly seen in patients with renal dysfunction (RD) , especially those with end -stage renal disease on hemodialysis (HD) , among whom the incidence and mortality of liver diseases increase. The development of direct - acting antiviral agents has revolutionized the therapy for chronic hepatitis C (CMC) with a sustained virologic response rate of >90% and a low rate of adverse events. Grazoprevir/elbasvir, paritaprevir/ritonavir + ombitasvir + dasabuvir, gleeaprevir/pibrentasvir, or daclatasvir + asu-naprevir regimen is recommended in CHC patients with RD and HD, while the sofosbuvir - based regimen is not recommended. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The current standard treatment for hepatitis C virus (HCV) infection is a combination of pegylated interferon (PEG-IFN) and ribavirin. However, it remains incurable in some patients. In recent years, direct acting antiviral agents (DAAs) that target specific HCV enzymes in HCV life cycle have been developed rapidly. A combination of PEG-IFN, ribavirin, and DAAs can increase the sustained virological response rate in patients with chronic hepatitis C (CHC). For patients who cannot use or tolerate interferon therapy, a combination of various DAAs has good efficacy. Therefore, DAAs bring new hope for the treatment of CHC. [ABSTRACT FROM AUTHOR]